A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved in the last years due to development and clinical approval of highly effective agents including immune checkpoint inhibitors (ICIs) and oncogene-directed therapies. Molecular profiling of lung cancer samples for activate...

Descripción completa

Detalles Bibliográficos
Autores principales: Santarpia, Mariacarmela, Massafra, Marco, Gebbia, Vittorio, D’Aquino, Antonio, Garipoli, Claudia, Altavilla, Giuseppe, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044480/
https://www.ncbi.nlm.nih.gov/pubmed/33889528
http://dx.doi.org/10.21037/tlcr-20-1113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044480/
https://www.ncbi.nlm.nih.gov/pubmed/33889528
http://dx.doi.org/10.21037/tlcr-20-1113

Ejemplares similares